Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Financing

Windward Bio closes $251.2M IPO and private placement, with underwriters' option exercised in full

Swiss clinical-stage biotech Windward Bio Group AG closed its Nasdaq IPO of 11,838,234 common shares at $17.00 each. The total includes the underwriters' full option of 1,544,117 shares. Gross proceeds, including a concurrent private placement, were about $251.2 million. Shares began trading on the Nasdaq Global Select Market as WWB on November 13, 2026. Windward is developing ultra-long-acting antibodies for respiratory and dermatologic diseases.

16 Nov 2026 · Windward Bio Group AG · Company news

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →